Persistent infection by several microbial agents is responsible for at least 15% of cancer
globally, including most cancers of the liver, stomach, and cervix. The recent development of …

Neutralizing antibody responses elicited during infection generally confer protection from
infection. Hepatitis C virus (HCV) encodes two glycoproteins E1 and E2 that are essential for …

Hepatitis C virus (HCV) infection is a global health challenge, and prophylactic vaccines are
the most effective way to eliminate the infection. To date, numerous forms of preventive …

Hepatitis C virus (HCV) infection is a major worldwide problem. Chronic hepatitis C is
recognized as one of the major causes of cirrhosis, hepatocellular carcinoma, and liver …

More than 120 million people worldwide are chronically infected with hepatitis C virus
(HCV), making HCV infection the leading cause of liver transplantation in developed …

The eradication of hepatitis C virus (HCV) infection is a public health priority. Despite the
efficiency of treatment with direct-acting antivirals, the high cost of the therapy and the lack of …

Hepatitis C Virus (HCV) infects 200 million individuals worldwide. Although several FDA
approved drugs targeting the HCV serine protease and polymerase have shown promising …

Background: Gradual development of a useful vaccine can be the main point in the control
and eradication of Hepatitis C virus (HCV) infection. Hepatitis C Virus envelope …

Development of heterologous systems to produce useful HCV vaccine candidates is an
important part of HCV research. In this study different HCV structural region variants were …

The reason (s) why human antibodies raised against hepatitis C virus (HCV) E2 epitopes do
not offer protection against multiple viral infections may be related to either genetic …